99
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Therapeutic potential of NAD-boosting molecules: the in vivo evidence

      research-article

      Read this article at

      ScienceOpenPublisherPMC
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Summary

          Nicotinamide adenine dinucleotide (NAD), the cell’s hydrogen carrier for redox enzymes, is well known for its role in redox reactions. More recently, it has emerged as a signaling molecule. By modulating NAD + sensing enzymes, it controls hundreds of key processes from energy metabolism to cell survival, rising and falling depending on food intake, exercise and the time of day. NAD + levels steadily decline with age, resulting in altered metabolism and increased disease susceptibility. Restoration of NAD + levels in old or diseased animals can promote health and extend lifespan, prompting a search for safe and efficacious NAD-boosting molecules. Such molecules hold the promise of increasing the body’s resilience, not just to one disease, but to many, thereby extending healthy human lifespan.

          eTOC Blurb

          Nicotinamide adenine nucleotide (NAD+) has emerged as a key regulator of cellular processes that control the body’s response to stress. Rajman et al. discuss NAD boosters, small molecules that raise NAD+ levels, which are now considered to be highly promising for the treatment of multiple diseases and the potential extension of human lifespan.

          Related collections

          Author and article information

          Journal
          101233170
          32527
          Cell Metab
          Cell Metab.
          Cell metabolism
          1550-4131
          1932-7420
          24 April 2018
          06 March 2018
          06 March 2019
          : 27
          : 3
          : 529-547
          Affiliations
          [1 ]Paul F. Glenn Center for the Biological Mechanisms of Aging, Department of Genetics, Harvard Medical School, Boston, MA 02115, USA
          [2 ]Laboratory for Ageing Research, Department of Pharmacology, School of Medical Sciences, The University of New South Wales, Sydney NSW 2052, Australia
          Author notes
          [# ]Lead contact and correspondence to: david_sinclair@ 123456hms.harvard.edu
          Article
          PMC6342515 PMC6342515 6342515 nihpa945421
          10.1016/j.cmet.2018.02.011
          6342515
          29514064
          3f17396f-4f5b-4bda-ba29-7254738170f6
          History
          Categories
          Article

          sirtuins,CD38,nicotinamide mononucleotide,epigenetics,cardiovascular disease,PARP1,aging,chromatin,inflammation,cancer,nicotinamide riboside,STAC

          Comments

          Comment on this article

          Related Documents Log